Research Analysts Offer Predictions for CRBP Q1 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Analysts at HC Wainwright cut their Q1 2026 EPS estimates for Corbus Pharmaceuticals in a note issued to investors on Monday, March 9th. HC Wainwright analyst A. Maldonado now anticipates that the biopharmaceutical company will post earnings per share of ($1.32) for the quarter, down from their previous forecast of ($1.31). The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. HC Wainwright also issued estimates for Corbus Pharmaceuticals’ Q2 2026 earnings at ($1.40) EPS, Q3 2026 earnings at ($1.47) EPS, Q4 2026 earnings at ($1.55) EPS, FY2026 earnings at ($5.74) EPS, FY2027 earnings at ($6.69) EPS, FY2028 earnings at ($5.00) EPS and FY2029 earnings at ($3.27) EPS.

A number of other research firms also recently commented on CRBP. Oppenheimer increased their price objective on Corbus Pharmaceuticals from $53.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Wednesday, January 21st. Royal Bank Of Canada decreased their price objective on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an “outperform” rating for the company in a report on Thursday, November 13th. Finally, Jefferies Financial Group raised shares of Corbus Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, February 18th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.71.

Corbus Pharmaceuticals Stock Up 3.9%

Corbus Pharmaceuticals stock opened at $10.43 on Thursday. The company’s fifty day simple moving average is $8.24 and its 200-day simple moving average is $10.54. Corbus Pharmaceuticals has a 12 month low of $4.64 and a 12 month high of $20.56. The stock has a market cap of $183.05 million, a P/E ratio of -1.74 and a beta of 2.84.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its quarterly earnings results on Monday, March 9th. The biopharmaceutical company reported ($1.25) EPS for the quarter, beating the consensus estimate of ($1.78) by $0.53.

Insider Activity at Corbus Pharmaceuticals

In related news, insider Dominic Smethurst sold 3,285 shares of the stock in a transaction dated Tuesday, February 3rd. The shares were sold at an average price of $8.09, for a total value of $26,575.65. Following the completion of the sale, the insider owned 95,887 shares in the company, valued at approximately $775,725.83. This trade represents a 3.31% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 3.60% of the company’s stock.

Hedge Funds Weigh In On Corbus Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in CRBP. Assenagon Asset Management S.A. acquired a new position in Corbus Pharmaceuticals in the 3rd quarter valued at approximately $1,080,000. Aberdeen Group plc grew its holdings in shares of Corbus Pharmaceuticals by 160.6% during the 3rd quarter. Aberdeen Group plc now owns 188,231 shares of the biopharmaceutical company’s stock worth $2,381,000 after purchasing an additional 116,005 shares in the last quarter. Baker Avenue Asset Management LP acquired a new stake in shares of Corbus Pharmaceuticals during the 2nd quarter worth approximately $138,000. Trexquant Investment LP increased its position in shares of Corbus Pharmaceuticals by 124.2% during the fourth quarter. Trexquant Investment LP now owns 27,275 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 15,110 shares during the period. Finally, Laurion Capital Management LP acquired a new position in shares of Corbus Pharmaceuticals in the fourth quarter valued at $151,000. 64.64% of the stock is currently owned by institutional investors.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of therapeutic candidates for rare, life-threatening inflammatory and fibrotic diseases. The company’s lead investigational therapy, lenabasum, is a synthetic, oral cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation by harnessing the body’s innate resolution pathways. Corbus operates by advancing small-molecule compounds through preclinical and clinical studies to address unmet medical needs in autoimmune and inflammatory disorders.

Lenabasum is currently under evaluation in a Phase 3 clinical trial for diffuse cutaneous systemic sclerosis (dcSSc) and in a Phase 2 study for cystic fibrosis–related inflammation.